NVCR250117P34000
- 4.20
- 0.000.00%
Novocure Newsroom
Investors in NovoCure (NASDAQ:NVCR) Have Seen Notable Returns of 97% Over the Past Year
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $46
Express News | Novocure Ltd - Appoints Ashley Cordova as CEO Effective Jan 1, 2025
NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.
Novocure Is Maintained at Overweight by Piper Sandler
NovoCure Analyst Ratings
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $42
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and NovoCure (NVCR)
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Why NovoCure Stock Was Winning Big This Week
Express News | Novocure Ltd : JP Morgan Raises Target Price to $29 From $19
A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $30 to $40
Zai Lab, Novocure Announce PANOVA-3 Trial Met Primary Endpoint
U.S. Small Caps Close Mixed As Novocure Lead, Archer Aviation Lags
12 Health Care Stocks Moving In Monday's Pre-Market Session
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating